Unknown

Dataset Information

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation.


ABSTRACT:

Background

Although successful treatment of papillary craniopharyngiomas (PCPs) with BRAFv600e inhibitors has been reported in clinical trials, studies have shown that approximately 10% of PCPs lack the BRAFv600e mutation and that BRAFv600e inhibitors may not be significantly effective against these tumors. However, no studies have focused specifically on BRAFv600e- PCPs.

Methods

Spatial transcriptome sequencing was performed on calcified PCP tissue to identify novel subtypes of PCP cells. The findings were validated via pathological methods in 51 PCP samples. Primary PCP cells from BRAFv600e- PCP patients and BRAFv600e+ PCP patients were isolated and then injected into the brains of nude mice via stereotactic surgery to establish a stable mo

SUBMITTER: Ainiwan Y 

PROVIDER: S-EPMC11874662 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature